MX391415B - Formulaciones de espuma rectal. - Google Patents
Formulaciones de espuma rectal.Info
- Publication number
- MX391415B MX391415B MX2019006924A MX2019006924A MX391415B MX 391415 B MX391415 B MX 391415B MX 2019006924 A MX2019006924 A MX 2019006924A MX 2019006924 A MX2019006924 A MX 2019006924A MX 391415 B MX391415 B MX 391415B
- Authority
- MX
- Mexico
- Prior art keywords
- foam formulations
- rectal foam
- rectal
- methods
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940096976 rectal foam Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 abstract 2
- 229960004963 mesalazine Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000006260 foam Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435265P | 2016-12-16 | 2016-12-16 | |
| PCT/IB2017/057954 WO2018109717A1 (en) | 2016-12-16 | 2017-12-14 | Rectal foam formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019006924A MX2019006924A (es) | 2019-10-09 |
| MX391415B true MX391415B (es) | 2025-03-21 |
Family
ID=60937825
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006924A MX391415B (es) | 2016-12-16 | 2017-12-14 | Formulaciones de espuma rectal. |
| MX2021016053A MX2021016053A (es) | 2016-12-16 | 2019-06-12 | Formulaciones de espuma rectal. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021016053A MX2021016053A (es) | 2016-12-16 | 2019-06-12 | Formulaciones de espuma rectal. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190351060A1 (https=) |
| EP (1) | EP3554473A1 (https=) |
| JP (2) | JP2020503296A (https=) |
| KR (1) | KR20190110092A (https=) |
| CN (1) | CN110430869A (https=) |
| AU (1) | AU2017377017A1 (https=) |
| BR (1) | BR112019012122A2 (https=) |
| CA (1) | CA3046938A1 (https=) |
| IL (1) | IL267347A (https=) |
| MX (2) | MX391415B (https=) |
| RU (1) | RU2757275C2 (https=) |
| WO (1) | WO2018109717A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3216267A1 (en) * | 2021-04-22 | 2022-10-27 | Glenn W. Laub | Foam compositions for treating clostridioides difficile infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8909559D0 (en) * | 1989-04-26 | 1989-06-14 | Smith Kline French Lab | Pharmaceutical compositions |
| SE9000485D0 (sv) * | 1990-02-09 | 1990-02-09 | Pharmacia Ab | Foamable composition for pharmaceutical use, use thereof and method of treatment |
| IT1243379B (it) * | 1990-07-27 | 1994-06-10 | Giuliani Spa | Composizione farmaceutica adatta alla somministrazione rettale di principi attivi che esplicano un'azione di medicazione a livello del colon prevalentemente di tipo topico |
| FR2713486B1 (fr) * | 1993-12-14 | 1996-02-09 | Scophysa | Nouvelles compositions pour mousses, notamment mousses rectales, et mousses ainsi obtenues. |
| DE4446891A1 (de) | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
| US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
| US20080069779A1 (en) * | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
| EP1663148A2 (en) * | 2003-08-25 | 2006-06-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
| AU2006298442A1 (en) * | 2005-05-09 | 2007-04-12 | Foamix Ltd. | Saccharide foamable compositions |
| WO2009150530A2 (en) * | 2008-06-11 | 2009-12-17 | Ferring International Center Sa | Novel foam composition |
| EP2140866A1 (en) * | 2008-07-04 | 2010-01-06 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract |
| RU2012126084A (ru) * | 2009-11-23 | 2013-12-27 | Сипла Лимитед | Пенная композиция для местного применения |
-
2017
- 2017-12-14 AU AU2017377017A patent/AU2017377017A1/en not_active Abandoned
- 2017-12-14 JP JP2019531779A patent/JP2020503296A/ja active Pending
- 2017-12-14 RU RU2019119495A patent/RU2757275C2/ru active
- 2017-12-14 EP EP17825956.0A patent/EP3554473A1/en not_active Withdrawn
- 2017-12-14 BR BR112019012122-6A patent/BR112019012122A2/pt not_active IP Right Cessation
- 2017-12-14 US US16/470,077 patent/US20190351060A1/en not_active Abandoned
- 2017-12-14 WO PCT/IB2017/057954 patent/WO2018109717A1/en not_active Ceased
- 2017-12-14 CN CN201780086722.5A patent/CN110430869A/zh active Pending
- 2017-12-14 CA CA3046938A patent/CA3046938A1/en not_active Abandoned
- 2017-12-14 KR KR1020197020401A patent/KR20190110092A/ko not_active Ceased
- 2017-12-14 MX MX2019006924A patent/MX391415B/es unknown
-
2019
- 2019-06-12 MX MX2021016053A patent/MX2021016053A/es unknown
- 2019-06-13 IL IL267347A patent/IL267347A/en unknown
-
2022
- 2022-08-16 JP JP2022129473A patent/JP2022163191A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017377017A1 (en) | 2019-07-04 |
| KR20190110092A (ko) | 2019-09-27 |
| JP2022163191A (ja) | 2022-10-25 |
| WO2018109717A1 (en) | 2018-06-21 |
| RU2757275C2 (ru) | 2021-10-12 |
| US20190351060A1 (en) | 2019-11-21 |
| CN110430869A (zh) | 2019-11-08 |
| BR112019012122A2 (pt) | 2019-11-05 |
| CA3046938A1 (en) | 2018-06-21 |
| EP3554473A1 (en) | 2019-10-23 |
| IL267347A (en) | 2019-08-29 |
| JP2020503296A (ja) | 2020-01-30 |
| RU2019119495A3 (https=) | 2021-03-24 |
| MX2019006924A (es) | 2019-10-09 |
| RU2019119495A (ru) | 2021-01-18 |
| MX2021016053A (es) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| DOP2017000280A (es) | Formas administración sólidas de palbociclib | |
| MX390014B (es) | Compuestos de dinucleótidos cíclicos y métodos de uso. | |
| PH12016502552A1 (en) | Formulation comprising a gemcitabine-prodrug | |
| MX390083B (es) | Formulaciones de (r)-2-amino-3-fenilpropil carbamato. | |
| MX2018008190A (es) | Sistemas y metodos para la administracion transdermica a largo plazo. | |
| MX390120B (es) | Moduladores de la somatostatina y usos de los mismos. | |
| CL2018000622A1 (es) | Acetamida tienodiazepinas de triazol y sus usos relacionados. | |
| BR112017004393A2 (pt) | formulações de anticorpo | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| UY36920A (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| MX391392B (es) | ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a. | |
| AR109376A1 (es) | FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA | |
| CL2019001053A1 (es) | Formulaciones farmacéuticas y métodos para prepararlas. | |
| CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
| MX391757B (es) | Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico. | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| CY1121105T1 (el) | Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv | |
| MX394833B (es) | Formulaciones con mejora de la estabilidad. | |
| BR112018071363A2 (pt) | composições farmacêuticas orais de nicotinamida | |
| JOP20170127A1 (ar) | صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات | |
| MX2021016053A (es) | Formulaciones de espuma rectal. | |
| MX390441B (es) | Formulaciones liquidas de fosfaplatino. | |
| MX383460B (es) | Derivados peptidicos novedosos y sus usos. |